Cargando…

Reduction in Acute Filariasis Morbidity during a Mass Drug Administration Trial to Eliminate Lymphatic Filariasis in Papua New Guinea

BACKGROUND: Acute painful swelling of the extremities and scrotum are debilitating clinical manifestations of Wuchereria bancrofti infection. The ongoing global program to eliminate filariasis using mass drug administration is expected to decrease this and other forms of filarial morbidity in the fu...

Descripción completa

Detalles Bibliográficos
Autores principales: Tisch, Daniel J., Alexander, Neal D. E., Kiniboro, Benson, Dagoro, Henry, Siba, Peter M., Bockarie, Moses J., Alpers, Michael P., Kazura, James W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3134431/
https://www.ncbi.nlm.nih.gov/pubmed/21765964
http://dx.doi.org/10.1371/journal.pntd.0001241
_version_ 1782207986689638400
author Tisch, Daniel J.
Alexander, Neal D. E.
Kiniboro, Benson
Dagoro, Henry
Siba, Peter M.
Bockarie, Moses J.
Alpers, Michael P.
Kazura, James W.
author_facet Tisch, Daniel J.
Alexander, Neal D. E.
Kiniboro, Benson
Dagoro, Henry
Siba, Peter M.
Bockarie, Moses J.
Alpers, Michael P.
Kazura, James W.
author_sort Tisch, Daniel J.
collection PubMed
description BACKGROUND: Acute painful swelling of the extremities and scrotum are debilitating clinical manifestations of Wuchereria bancrofti infection. The ongoing global program to eliminate filariasis using mass drug administration is expected to decrease this and other forms of filarial morbidity in the future by preventing establishment of new infections as a consequence of eliminating transmission by the mosquito vector. We examined whether mass treatment with anti-filarial drugs has a more immediate health benefit by monitoring acute filariasis morbidity in Papua New Guinean communities that participated in a 5-year mass drug administration trial. METHODOLOGY/PRINCIPAL FINDINGS: Weekly active surveillance for acute filariasis morbidity defined by painful swelling of the extremities, scrotum and breast was performed 1 year before and each year after 4 annual mass administrations of anti-filarial drugs (16,480 person-years of observation). Acute morbidity events lasted <3 weeks in 92% of affected individuals and primarily involved the leg (74–79% of all annual events). The incidence for all communities considered together decreased from 0.39 per person-year in the pre-treatment year to 0.31, 0.15, 0.19 and 0.20 after each of 4 annual treatments (p<0.0001). Residents of communities with high pre-treatment transmission intensities (224–742 infective bites/person/year) experienced a greater reduction in acute morbidity (0.62 episodes per person-year pre-treatment vs. 0.30 in the 4(th) post-treatment year) than residents of communities with moderate pre-treatment transmission intensities (24–167 infective bites/person/year; 0.28 episodes per person-year pre-treatment vs. 0.16 in the 4(th) post-treatment year). CONCLUSIONS: Mass administration of anti-filarial drugs results in immediate health benefit by decreasing the incidence of acute attacks of leg and arm swelling in people with pre-existing infection. Reduction in acute filariasis morbidity parallels decreased transmission intensity, suggesting that continuing exposure to infective mosquitoes is involved in the pathogenesis of acute filariasis morbidity.
format Online
Article
Text
id pubmed-3134431
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-31344312011-07-15 Reduction in Acute Filariasis Morbidity during a Mass Drug Administration Trial to Eliminate Lymphatic Filariasis in Papua New Guinea Tisch, Daniel J. Alexander, Neal D. E. Kiniboro, Benson Dagoro, Henry Siba, Peter M. Bockarie, Moses J. Alpers, Michael P. Kazura, James W. PLoS Negl Trop Dis Research Article BACKGROUND: Acute painful swelling of the extremities and scrotum are debilitating clinical manifestations of Wuchereria bancrofti infection. The ongoing global program to eliminate filariasis using mass drug administration is expected to decrease this and other forms of filarial morbidity in the future by preventing establishment of new infections as a consequence of eliminating transmission by the mosquito vector. We examined whether mass treatment with anti-filarial drugs has a more immediate health benefit by monitoring acute filariasis morbidity in Papua New Guinean communities that participated in a 5-year mass drug administration trial. METHODOLOGY/PRINCIPAL FINDINGS: Weekly active surveillance for acute filariasis morbidity defined by painful swelling of the extremities, scrotum and breast was performed 1 year before and each year after 4 annual mass administrations of anti-filarial drugs (16,480 person-years of observation). Acute morbidity events lasted <3 weeks in 92% of affected individuals and primarily involved the leg (74–79% of all annual events). The incidence for all communities considered together decreased from 0.39 per person-year in the pre-treatment year to 0.31, 0.15, 0.19 and 0.20 after each of 4 annual treatments (p<0.0001). Residents of communities with high pre-treatment transmission intensities (224–742 infective bites/person/year) experienced a greater reduction in acute morbidity (0.62 episodes per person-year pre-treatment vs. 0.30 in the 4(th) post-treatment year) than residents of communities with moderate pre-treatment transmission intensities (24–167 infective bites/person/year; 0.28 episodes per person-year pre-treatment vs. 0.16 in the 4(th) post-treatment year). CONCLUSIONS: Mass administration of anti-filarial drugs results in immediate health benefit by decreasing the incidence of acute attacks of leg and arm swelling in people with pre-existing infection. Reduction in acute filariasis morbidity parallels decreased transmission intensity, suggesting that continuing exposure to infective mosquitoes is involved in the pathogenesis of acute filariasis morbidity. Public Library of Science 2011-07-12 /pmc/articles/PMC3134431/ /pubmed/21765964 http://dx.doi.org/10.1371/journal.pntd.0001241 Text en Tisch et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Tisch, Daniel J.
Alexander, Neal D. E.
Kiniboro, Benson
Dagoro, Henry
Siba, Peter M.
Bockarie, Moses J.
Alpers, Michael P.
Kazura, James W.
Reduction in Acute Filariasis Morbidity during a Mass Drug Administration Trial to Eliminate Lymphatic Filariasis in Papua New Guinea
title Reduction in Acute Filariasis Morbidity during a Mass Drug Administration Trial to Eliminate Lymphatic Filariasis in Papua New Guinea
title_full Reduction in Acute Filariasis Morbidity during a Mass Drug Administration Trial to Eliminate Lymphatic Filariasis in Papua New Guinea
title_fullStr Reduction in Acute Filariasis Morbidity during a Mass Drug Administration Trial to Eliminate Lymphatic Filariasis in Papua New Guinea
title_full_unstemmed Reduction in Acute Filariasis Morbidity during a Mass Drug Administration Trial to Eliminate Lymphatic Filariasis in Papua New Guinea
title_short Reduction in Acute Filariasis Morbidity during a Mass Drug Administration Trial to Eliminate Lymphatic Filariasis in Papua New Guinea
title_sort reduction in acute filariasis morbidity during a mass drug administration trial to eliminate lymphatic filariasis in papua new guinea
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3134431/
https://www.ncbi.nlm.nih.gov/pubmed/21765964
http://dx.doi.org/10.1371/journal.pntd.0001241
work_keys_str_mv AT tischdanielj reductioninacutefilariasismorbidityduringamassdrugadministrationtrialtoeliminatelymphaticfilariasisinpapuanewguinea
AT alexandernealde reductioninacutefilariasismorbidityduringamassdrugadministrationtrialtoeliminatelymphaticfilariasisinpapuanewguinea
AT kiniborobenson reductioninacutefilariasismorbidityduringamassdrugadministrationtrialtoeliminatelymphaticfilariasisinpapuanewguinea
AT dagorohenry reductioninacutefilariasismorbidityduringamassdrugadministrationtrialtoeliminatelymphaticfilariasisinpapuanewguinea
AT sibapeterm reductioninacutefilariasismorbidityduringamassdrugadministrationtrialtoeliminatelymphaticfilariasisinpapuanewguinea
AT bockariemosesj reductioninacutefilariasismorbidityduringamassdrugadministrationtrialtoeliminatelymphaticfilariasisinpapuanewguinea
AT alpersmichaelp reductioninacutefilariasismorbidityduringamassdrugadministrationtrialtoeliminatelymphaticfilariasisinpapuanewguinea
AT kazurajamesw reductioninacutefilariasismorbidityduringamassdrugadministrationtrialtoeliminatelymphaticfilariasisinpapuanewguinea